Berjaya (KLSE:BJCORP) said Vincent Tan sold 461.65 million shares of the company across seven transactions on May 28, according to a Thursday Malaysian bourse filing.
The Malaysian tycoon now owns 4.11% in direct interest and 10.96% in deemed interest in the conglomerate.
The latest disposal follows the reported sale of a 5.25% stake in Berjaya in March.
China's onshore ESG-labeled bond issuance dropped 21% year on year in the first quarter, following a strong 70% rebound in 2025, according to a Wednesday news release from Sustainable Fitch.Offshore issuance remained subdued, though sovereign activity supported early Q2 momentum.Onshore social bonds were resilient, with corporate participation broadening across utilities and infrastructure.ESG-labeled panda bond issuance doubled annually in Q1, driven by competitive renminbi funding rates, but remained a small fraction of total panda bonds.
Nagase & Co. (TYO:8012) has developed a starch-based superabsorbent polymer (SAP) to replace the petroleum-based materials traditionally used in diapers and sanitary pads, Nikkei Asia reported Thursday, citing an official.Japanese startup VVV is releasing a women's incontinence pad on Thursday that uses Nagase's new material, the report said.Nagase developed the material to reduce reliance on naphtha (petroleum) and avoid supply chain disruptions from the Middle East, according to the report.Nagase developed the material in 2023 by combining its subsidiaries' expertise in enzymes and semiconductor-grade plastics.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) has received board approval to surrender its factory license to the Department of Factories, Boilers, Industrial Safety and Health, India, for cancellation, according to a Wednesday filing to the Indian stock exchanges.The license is valid from Dec. 14, 2023, to Dec. 31.The move follows the pharmaceutical company's earlier disclosures about exiting its manufacturing site and surrendering its manufacturing license.